Sarepta Therapeutics Inc (SRPT)

Financial leverage ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Total assets	US$ in thousands	3,224,380	3,264,580	3,109,710	3,125,890	3,059,790	3,128,370	3,156,150	2,996,850	3,056,150	3,147,970	2,662,220	2,759,070	2,765,230	2,984,720	2,780,660	2,883,040	2,947,390	1,822,820	1,702,470	1,747,750
Total stockholders’ equity	US$ in thousands	961,192	859,337	764,357	741,411	712,749	384,950	430,840	726,457	856,886	928,009	469,528	485,108	535,445	761,759	892,047	1,042,870	1,144,830	818,187	995,204	1,099,170
Financial leverage ratio		3.35	3.80	4.07	4.22	4.29	8.13	7.33	4.13	3.57	3.39	5.67	5.69	5.16	3.92	3.12	2.76	2.57	2.23	1.71	1.59

March 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $3,224,380K ÷ $961,192K
= 3.35

The financial leverage ratio of Sarepta Therapeutics Inc has fluctuated over the past few quarters, indicating changes in the company's debt levels relative to its equity. The trend shows an upward movement in the financial leverage ratio from the end of 2021 to the middle of 2022, reaching a peak at 8.13 in December 2022. This increase suggests that the company was relying more on debt financing during that period.

However, from December 2022 onwards, there has been a downward trend in the financial leverage ratio, indicating a decrease in the proportion of debt in the company's capital structure compared to equity. By the end of March 2024, the financial leverage ratio had decreased to 3.35, which is a significantly lower level compared to the peak in late 2022.

Overall, the decreasing trend in the financial leverage ratio from late 2022 to early 2024 may suggest that Sarepta Therapeutics Inc has been managing its debt levels effectively and potentially reducing its financial risk by relying less on debt financing and strengthening its equity position. However, it is essential to continue monitoring this ratio to assess the company's capital structure stability and financial health.